Its a clever idea, but its far from perfect
Young: Right, so Novo Nordisk essentially sued Hims & Hers because they were saying that, Hey, youre mismarketing your compounded GLP-1s as essentially a first go-to drug instead of our drug. They also were alleging them to be, like, copycats. And these drugs under Novo Nordisk and similarly Eli Lilly, theyre still under patent
Success in this environment requires a balanced approach to portfolio management knowing both when to invest in promising categories and when to exit declining ones, guided by sophisticated market intelligence and predictive analytics
RetaTracker helps you keep your GLP-1 journey organized with simple tracking for weight, hydration, protein, symptoms, food noise, mood, injection notes, and provider questions
This cold-chain protocol is non-negotiable
This suggests that IGFBP-3 downregulation may mediate the oncogenic action of high miR-19a-3p expression in ovarian cancer [54]